Investor Presentation

2022 Confidential & Proprietary to Owens & Minor, Inc. 1

This presentation contains certain "forward looking"

statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the proposed transaction with Apria, Inc. ("Apria")

and opportunities related thereto, expectations with respect to our financial performance and related assumptions, the Owens & Minor, Inc.'s ("Owens & Minor" or the "Company") business, the impact of COVID-19 on

the Company's results and operations, and the Company's financial targets. Forward looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those

projected, targeted or contemplated in the forward looking statements, including that the proposed transaction will not be completed on a timely basis or at all, whether due to the failure to satisfy the conditions of the related agreement

(including approvals or clearances from regulatory and other agencies and bodies) or otherwise, the possibility that stockholders of Apria may not approve the transaction, the risk that problems may arise in successfully integrating the businesses

of the companies, which may result in the combined company not operating as effectively and efficiently as expected and the risk that the combined company may be unable to achieve synergies or that it may take longer than expected to achieve those

synergies. Investors should refer to each of Owens & Minor's and Apria's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC, including the sections captioned "Cautionary Note Regarding Forward

Looking Statements" and "Item 1A. Risk Factors," and subsequent current reports on Form 8-K filed with the SEC, for a discussion of certain known risk factors that could cause the Company's actual results to differ materially

from those projected, targeted or contemplated in the forward looking statements. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions

investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward- Safe Harbor looking statements, as a result of new information, future developments or otherwise. This

presentation includes certain combined financial information which reflects the sum of the relevant financial information for the Company and Apria without any other adjustments and refer to such presentation as on a "combined" basis for

the applicable period. This combination does not comply with U.S. GAAP or with the rules for pro forma presentation. As a result, the combined financial information included in this presentation may differ from pro forma financial information

prepared in accordance with U.S. GAAP and the rules and regulations of the SEC, and any such differences could be material. Numerical figures included in this presentation have been subject to rounding adjustments. Accordingly, numerical figures

shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. As such, the corresponding percentage aggregations may not sum to 100%. We present certain potential cost savings as an adjustment to Combined

Adjusted EBITDA because we expect them to be a permitted addback pursuant to agreements that govern our indebtedness. These potential cost savings are based on assumptions and estimates that could be proved to be incorrect, and accordingly should

not be viewed as a projection of future performance. Certain financial measures included herein are not made in accordance with U.S. GAAP and use of such terms varies from others in the same industry. Management uses these non-GAAP financial

measures internally to evaluate our performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation. Non-GAAP financial measures should not be considered as alternatives to measures derived

in accordance with U.S. GAAP. Non-GAAP financial measures have important limitations as analytical tools and you should not consider them in isolation or as substitutes for results as reported under U.S. GAAP. The appendix to this presentation

includes a reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated in accordance with U.S. GAAP. C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns

s & & M Mino inor r,, IIn nc c.. 2 2

Today's Presenters Ed Pesicka Jonathan Leon Andy Long President

& CEO SVP, Corporate Treasurer EVP, Chief Financial Officer C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 3 3

Executive Summary C Co on nffide iden nttial ial & & P Pr ro op

pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 4 4

Introduction and Transaction Overview On January 7th Owens &

Minor, Inc. ("OMI" or the "Company") entered into a definitive agreement (the "Transaction") to acquire 1 ~$1,598 million Transaction Value Apria, Inc. ("Apria" or the "Target") 1 -

Transaction value of ~$1,598 million ($37.50 in cash per share) 2 represents ~7x FY 2021 Adjusted EBITDA of $232 million , excluding fees and expenses Adds $232 million in FY 2021 Adjusted Adjusted EBITDA 2 EBITDA OMI is a global healthcare

solutions and products provider with a soft goods durable medical equipment ("DME") focused patient direct business ~7x Transaction value (based on FY 2021 2 - For FY 2021, Revenue and Adjusted EBITDA are $9.8 billion and EV Multiple

Adjusted EBITDA) 4 $597 million , respectively Apria offers products and services for in-home care across its core service lines: Home Respiratory Therapy, Obstructive Sleep Apnea 3 ("OSA"), Negative Pressure Wound Therapy

("NPWT"), and Home Cash on hand plus additional debt Funding Medical Equipment ("HME") and other services. The Transaction is intended to create a stronger, faster-growing and more diversified company st Expected

closing in 1 half of 2022 Timeline - Apria expands OMI's presence in the high-growth home healthcare market by complimenting and diversifying the Company's existing home-based care business, Byram Healthcare - The Transaction is expected

to be accretive to revenue and Apria stockholder vote Approvals EBITDA, and enhances FCF generation, enabling OMI to deleverage while continuing to invest across the business Note: Apria financials as of 12/31/2021 per earnings release 2/28/22 1 2

Transaction value defined as fully diluted market capitalization at $37.50 per share, plus total debt, less cash; Adjusted EBITDA is a non-GAAP measure. For a reconciliation of Net Income, the most directly comparable GAAP measure, to Adjusted

EBITDA, 3 see slides 34-36; OMI has obtained debt financing commitments to finance the Transaction and pay related fees and expenses in the form of (i) a term loan B facility in an aggregate principal amount of $1.9 billion and (ii) an increase to

the revolving 4 commitments under its existing credit agreement in an aggregate principal amount of $150 million (currently provides for $450 million of borrowing capacity), each subject to customary conditions; Adjusted EBITDA for 2021 reflects

adjustments for public company costs of approximately $8.6mm one-time, non-recurring costs and expenses of $10.0mm and realized losses from swaps/derivatives of $4.8mm. These adjustments reflect a change in presentation of Adjusted EBITDA

implemented in 2021 that is C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 5 5 permitted under the agreements governing our indebtedness, but corresponding

adjustments were not included in prior periods.

OMI Overview: Leading Healthcare Solutions Provider A growth-focused,

integrated healthcare solutions provider with broad medical distribution reach, proprietary products and services, and a leading home health business that empowers our customers to advance healthcare 140 years of legacy service

Extensive medical distribution platform and network of trusted relationships Large North American manufacturing footprint that helps serve PPE needs Supported by value-added services and technology solutions that drive recurring

revenue and "sticky" partnerships 15,000+ 1,200+ 4,000+ 95+ Portfolio of proprietary products and emerging home health Teammates Branded Healthcare Facilities business that we expect will fuel growth Worldwide Manufacturers

Providers Worldwide Served Record of strong growth in Patient Direct business since acquiring Byram Healthcare, expected to be augmented by strategic acquisition of Apria C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar

ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 6 6

How Our Businesses Work Together Today Seamlessly operate our

Americas-based manufacturing and provide support through the hospital and into the home DESIGN RAW MANUFACTURING DISTRIBUTION DELIVERY HOSPITAL/IDN HOME HEALTH CHRONIC CARE AT HOME MATERIALS 1,200+ Branded Medical Product Suppliers N E W P A T I E N

T D I R E C T N E W P R O D U C T S & H E A L T H C A R E S E R V I C E S S E G M E N T S E G M E N T Our Value Chain is a Key Differentiator C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s &

& M Mino inor r,, IIn nc c.. 7 7

Alternate Care Market Overview Byram competes primarily in the soft

goods DME market Byram also competes in the Home Health Agency Market, Chronic Care accounting for an additional at Home (DME Home Health & Overall DME: ~ $50bn Soft Goods) $750mm in B2B Supply Hospice 2021 - 2023 Growth: 6% Spending LTC / SNFs

/ DME Rehabs / Sub- (Respiratory Acute Care Equipment) Facilities Expansion into mobile Health ("mHealth"), Cash/Retail and mHealth / Remote Cash / Retail other verticals (e.g. Monitoring Respiratory) are actively being explored

Medications/ Pharmacy Fragmented Channels for Delivery of Medical Products & Services C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 8 8 8

Current Leader in Fast Growing Home Health Sector Byram key highlights

Direct-to-patient distributor of medical supplies to U.S. patients with chronic diseases Specializes in diabetes, urology, ostomy, wound care, incontinence, and breast pumps In network provider with over 85% of U.S. insured

lives covered 650+ Managed Care contracts Center of Excellence Reimbursement Center National footprint, Regional presence Core Geographic Markets Distribution Center Insurance reimbursement and billing Sales & Service

Center expertise C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 9 9

Apria Builds on OMI's Success in the Patient Direct Segment

Leading provider of integrated home healthcare Provides home healthcare therapies requiring equipment and related services in the U.S. high-touch service Offers a comprehensive range of products and Expertise in

fee-for service as well as services for in-home care and delivery across: capitation arrangements Home respiratory ~6,500 employees serving approximately Obstructive sleep apnea 2 million patients annually Negative

pressure wound therapy Payor mix 78% commercial, 21% Medicare, 1% Home medical equipment and other services Medicaid Geographic Footprint Product Categories Strong Payor Relationships HME & Other NPWT Services Obstructive Home

Respiratory Sleep Apnea C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 10 10

Summary of Strategic Rationale Apria Expands Critical Patient Direct

Segment Patient Direct Product Lines Well-positioned across key product categories exposed to Home Respiratory strong underlying growth drivers Obstructive Sleep Apnea Expands offerings across chronic and acute conditions, with opportunities to

treat overlapping conditions for patients Negative Pressure Wound Therapy HME & Other Services More expansive geographic reach Diabetes Expands payor relationships Ostomy Incontinence Brings greater efficiency to the home healthcare supply

market Traditional Wound Care History of strong performance by the Byram team instills confidence and excitement around Apria acquisition Urology Track record of profitable growth and value creation by Apria Breast Pumps team C Co on nffide iden

nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 11 11

Combined Company Profile Combined OMI is a global healthcare

services company Apria is a provider of durable home healthcare Global Global and distributor of medical and surgical supplies equipment and related services in the U.S., Solutions Solutions offering a range of products and services for in-

The Company operates through two segments: home care and delivery across four services Global Products and Global Solutions lines: Global Global Global Solutions: 80% of 2021 net revenue Home Respiratory Patient Products

Products Obstructive Sleep Apnea Direct Global Products 20% of 2021 net revenues Negative pressure wound therapy Home medical equipment and other services Patient Patient Apria provides home healthcare

therapies that Direct require high touch service, often acting as a Direct bridge from the acute to home setting 2 2,4 2021 Revenue: $9,785mm 2021 Net Revenue: $1,145mm Summary Summary Summary Combined 2021 Net Revenue: $10,931mm 4,5 1,5 1 Combined

2021 Adjusted EBITDA: $839mm Financials Financials Financials 2021 Adjusted EBITDA: $597mm 2021 Adjusted EBITDA : $232mm 4 Patient Direct Combined Patient Direct (Byram+ Apria) Global Solutions 4 Global Products Combined Products and Healthcare

Services ~20% Segment Combined 3 3 EBITDA EBITDA 4 EBITDA ~49% ~51% ~80% 100% Note: Apria financials as of 12/31/2021 per earnings release 2/28/22 1 2 Adjusted EBITDA is a non-GAAP measure. For a reconciliation of Net Income, the most directly

comparable GAAP measure, to Adjusted EBITDA, see slides 34-36; Global Products Revenue / operating income net of inter-segment Revenue / operating 3 4 income of $730.9mm and $3.8mm, respectively for 2021; Based on segment EBITDA for OMI and Apria

reported EBITDA; see slide 35; Combined numbers are non-GAAP and reflect the summation of OMI plus Apria. Combined EBITDA also reflect C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino

inor r,, IIn nc c.. 12 12 5 $10mm of potential cost savings. See slide 2 for more information regarding OMI and Apria combined measures and important limitations; Adjusted EBITDA for 2021 reflects adjustments for public company costs of

approximately $8.6mm one-time, non-recurring costs and expenses of $10.0mm and realized losses from swaps/derivatives of $4.8mm. These adjustments reflect a change in presentation of Adjusted EBITDA implemented in 2021 that is permitted under the

agreements governing our indebtedness, but corresponding adjustments were not included in prior periods.

Key Credit Highlights C Co on nffide iden nttial ial & & P Pr

ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 13 13

Key Credit Highlights Summary 1 Favorable trends driving robust demand

2 One of the market leaders in fast growing home health sector 3 Vertical integration creates stability and competitive advantage 4 Diverse earnings profile across customers, payors, products and geographies 5 Low leverage and strong cash flow

generation 6 Experienced management with proven track record of success C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 14 14

1 Favorable Trends Driving Robust Demand 1 Durable Medical Equipment

Expenditures: Historic and Projected (CMS) ($bn) 98 93 88 83 78 74 70 66 57 55 55 52 51 49 47 45 44 42 40 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021E 2022E 2023E 2024E 2025E 2026E 2027E 2028E A Ag giin ng g p po op pu ulla ati tio

on n U.S. population aged 65+ will grow substantially from 15.2% to 20.6% of the population between 2016 and 2030 R Riis siin ng g iin nc ciid de en nc ce e o of f Increasing obesity rates and historically high prevalence of smoking

will drive diagnosis rates for a number of chronic conditions c ch hr ro on niic c d diis se ea as se es s Certain chronic diseases currently under-diagnosed Home healthcare increasingly sought out as an attractive, cost-effective

and clinically appropriate alternative to facility-based care C Co on nti tin nu ue ed d s sh hiift ft to tow wa ar rd d h ho om me e h he ea allth thc ca ar re e Pandemic environment further emphasized the need for home healthcare as a

low-risk setting Improved technology has increased number of treatments administered at home Pr Pre efe fer re en nc ce e fo for r in in- -h ho om me e c ca ar re e Patients prefer the convenience of in-home care H Hiig gh hlly y fr

fra ag gm me en nte ted d Between 2012 and 2018, the overall number of durable medical equipment, prosthetics, orthotics and supplies suppliers that bill Medicare more than $10mm annually fell from 73 to 57 market market The market

remains highly fragmented and competitive Source: CMS, United States Census Bureau, Medicare Payment Advisory Commission, HME News, and Henry J. Kaiser Family Foundation 1 The latest projections were published in 2018 and are shown from 2021 through

2028. These projections do not take into account the impact of COVID-19 because of the timing of the report and the highly uncertain nature of the pandemic. 2019 and 2020 actual results were sourced from CMS. C Co on nffide iden nttial ial &

& P Pr ro op pr riet ieta ar ry y tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 15 15

1 Favorable Trends Driving Robust Demand (cont'd) PPE Impact on

Global Products Volume PPE Demand Opportunities for growth exist beyond COVID-enhanced levels with the return of elective procedures and demand for PPE in new industries Revised healthcare protocols and new customer stockpiling requirements driving

increased use of PPE National demand for stockpile recovery Increased use of PPE in both healthcare and non-healthcare settings Preference for medical grade PPE by healthcare professionals Customer growth Surge abates, but normalized levels remain

higher due to new healthcare protocols and new markets New end markets, including Industrial, Specialty and International Market Opportunity is Much Greater Than Pre-Pandemic C Co on nffide iden nttial ial & & P Pr ro op pr riet ieta ar ry y

tto o Ow Owe en ns s & & M Mino inor r,, IIn nc c.. 16 16